Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of GSK1349572 50 mg once daily vs raltegravir in treatment-naïve HIV-1 infected adults
2009-017950-11Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Proportion of subjects with HIV-1 RNA < 50 copies/mL. Started Aug 2010; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2009-017950-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017950-11.